0001787306-24-000020.txt : 20240215 0001787306-24-000020.hdr.sgml : 20240215 20240215183610 ACCESSION NUMBER: 0001787306-24-000020 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240213 FILED AS OF DATE: 20240215 DATE AS OF CHANGE: 20240215 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Burnett Patrick CENTRAL INDEX KEY: 0001741987 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39186 FILM NUMBER: 24645288 MAIL ADDRESS: STREET 1: C/O VERRICA PHARMACEUTICALS INC. STREET 2: 10 NORTH HIGH STREET, SUITE 200 CITY: WEST CHESTER STATE: PA ZIP: 19380 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Arcutis Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001787306 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 812974255 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3027 TOWNSGATE ROAD STREET 2: SUITE 300 CITY: WESTLAKE VILLAGE STATE: CA ZIP: 91361 BUSINESS PHONE: 805-418-5006 MAIL ADDRESS: STREET 1: 3027 TOWNSGATE ROAD STREET 2: SUITE 300 CITY: WESTLAKE VILLAGE STATE: CA ZIP: 91361 FORMER COMPANY: FORMER CONFORMED NAME: Arcutis, Inc. DATE OF NAME CHANGE: 20190905 4 1 wk-form4_1708040155.xml FORM 4 X0508 4 2024-02-13 0 0001787306 Arcutis Biotherapeutics, Inc. ARQT 0001741987 Burnett Patrick C/O ARCUTIS BIOTHERAPEUTICS, INC. 3027 TOWNSGATE ROAD SUITE 300 WESTLAKE VILLAGE CA 91361 0 1 0 0 See Remarks 0 Common Stock 2024-02-13 4 A 0 128000 A 213032 D Common Stock 2024-02-13 4 A 0 9600 A 222632 D Common Stock 2024-02-13 4 A 0 23550 A 246182 D Common Stock 2024-02-13 4 A 0 27900 A 274082 D Stock Option (right to buy) 25.89 2024-02-13 4 D 0 320000 D 2030-08-03 Common Stock 320000 0 D Stock Option (right to buy) 32.44 2024-02-13 4 D 0 28800 D 2031-03-02 Common Stock 28800 0 D Stock Option (right to buy) 17.67 2024-02-13 4 D 0 47100 D 2032-03-03 Common Stock 47100 0 D Stock Option (right to buy) 15.82 2024-02-13 4 D 0 55800 D 2033-03-02 Common Stock 55800 0 D On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on August 3, 2020, and received in exchange for the option, these Restricted Stock Units ("RSUs") that vest in four equal quarterly installments commencing May 1, 2024. On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 3, 2021, and received in exchange for the option, these RSUs that vest in eight equal quarterly installments commencing May 1, 2024 On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 3, 2022, and received in exchange for the option, these RSUs that vest in eight equal quarterly installments commencing May 1, 2024. On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 2, 2023, and received in exchange for the option, these RSUs that vest in twelve equal quarterly installments commencing May 1, 2024. The canceled option vested as to 1/4 of the total shares on August 1, 2021, and then 1/48 of the total shares vest monthly thereafter, with 100% of the total shares vesting on August 1, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The canceled option vest as to 1/48 of the shares subject to the option vest on each monthly anniversary measured from March 3, 2021 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. The canceled option vest as to 1/48 of the shares subject to the option vest on each monthly anniversary measured from March 1, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. The canceled option vest as to 1/48 of the shares subject to the option vest on each monthly anniversary measured from March 1, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Reporting Person's title: Senior Vice President, Chief Medical Officer /s/ John W. Smither, as Attorney-in-Fact for Patrick Burnett 2024-02-15